Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit KRAS directly have been unsuccessful. Our previous studies showed that inhibition of cyclin-dependent kinase 5 (CDK5), reduces pancreatic cancer growth and progression, th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Hu, Chaoxin, Dadon, Tikva, Chenna, Venugopal, Yabuuchi, Shinichi, Bannerji, Rajat, Booher, Robert, Strack, Peter, Azad, Nilofer, Nelkin, Barry D., Maitra, Anirban
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497872/
https://ncbi.nlm.nih.gov/pubmed/25931518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0028
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares